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A large proportion of patients with rheumatic disease have an immunocompromised status resulting from disease pathogenesis 
itself and/or several immunosuppressive drugs including biologics. These conditions are closely related to a higher risk of a vari-
ety of infectious diseases. Therefore, a few vaccinations for vaccine-preventable pathogens should be considered in patients 
with rheumatic disease at the appropriate time. The quadrivalent inactivated influenza and pneumococcal vaccinations, includ-
ing both 13-valent conjugate and 23-valent polysaccharide vaccines, are strongly recommended in all patients with rheumatic 
disease. The immunogenicity of influenza and pneumococcal vaccination have generally been demonstrated in patients with 
rheumatic disease on biologics except for rituximab and abatacept. Vaccines can be administered during therapy with tumor 
necrosis factor-α antagonists but may be more ideal during a stable or remission status without immunosuppressive therapy. 
In particular, vaccination should be done at least 6 months after an injection of rituximab as a B-lymphocyte-depleting biologic. 
Basically, all live-attenuated vaccines should be avoided in highly immunocompromised rheumatic disease patients. The vacci-
nation for herpes zoster (HZ) can be taken carefully according to degree of immunosuppression because the currently available 
vaccine is only live-attenuated. The newly developed subunit HZ vaccine is promising in immunocompromised patients with 
rheumatic disease. (J Rheum Dis 2018;25:100-107)
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INTRODUCTION
In general, patients with rheumatic disease including 
ankylosing spondylitis (AS), rheumatoid arthritis (RA) 
and psoriatic arthritis (PsA) are more vulnerable to a wide 
array of infectious diseases than in the healthy general 
population, because immunosenescence or immune ex-
haustion by long-term persistent immune activating con-
ditions in rheumatic disease could lead to impaired im-
mune defense system against various pathogens and/or 
they are frequently exposed to several immunomodulat-
ing or immunosuppressive drugs [1-7]. In particular, the 
biologic agents becoming widespread in the past decade, 
which are directly targeting specific pro-inflammatory 
markers and signal pathways of innate or adaptive im-
mune system, could apparently skew the immune func-
tion against certain microbes [7-12]. 
Some causative pathogens of infectious complications 
with high risk in patients with rheumatic disease can be 
prevented by active immunization. Therefore, several vac-
cination, which are essential in other immunocompromied 
patients including transplant recipients and chronic med-
ical diseases such as diabetes mellitus or chronic pulmo-
nary/renal diseases or solid cancers, are necessary to be 
applied in patients with rheumatic disease [13,14]. 
Importantly, physicians may take notice of two distinctive 
features for vaccination in patients with rheumatic 
disease. First, the defective immune functions by various 
causes could decrease the efficiency and/or immunogenicity 
of humoral or cellular immunity from vaccination. 
Consequently, the adequate preventable responses could 
not be arisen in spite of immunization [15-17]. Second, 
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extrinsic further antigenic stimulation of vaccination 
might trigger a nonspecific immune response, potentially 
resulting in increased activity of rheumatic disease called 
rheumatic complications. Therefore, we need to pay at-
tention to short and/or long-term side effects by vacci-
nation [1,18]. 
In addition, we may apply to different vaccination strat-
egies for mildly or highly immunocompromised rheu-
matic disease patients because of careful consideration 
for efficiency of vaccination and contraindication of a few 
live attenuated vaccines [1]. The mildly immunocompro-
mised rheumatic disease patients are considered to those 
treated with (1) ≤2 weeks of corticosteroid, (2) low to 
moderate doses of corticosteroids (＜20 mg/day of pre-
dnisone), (3) local injection of corticosteroids, (4) long-term 
treatment with low to moderate doses of short-acting cor-
ticosteroids, (5) methotrexate (＜0.4 mg/kg/week, e.g., 25 
mg/week), or (6) azathioprine (＜3.0 mg/kg/day). 
Otherwise, the highly immunocompromised rheumatic 
disease patients are considered to those treated with tu-
mor necrosis factor (TNF)-α antagonists, nonbiologic 
disease-modifying antirheumatic drugs (DMARDs), par-
ticularly cyclophosphamide or azathioprine, and cortico-
steroids with high amount exceeding above mild con-
ditions [14].
In this review, we will address a few vaccines including 
seasonal influenza, Streptococcus pneumoniae, and herpes 
zoster (HZ), which are necessary to be taken into account 
to adult patients with rheumatic disease, especially focus-
ing on those receiving with biologics.
MAIN SUBJECTS
Risk of vaccine-preventable infectious diseases in 
patients with rheumatic disease
Although the incidence varies between a wide range of 
types and disease activities of rheumatic disease as well as 
characteristics of immunosuppressive and disease-modi-
fying agents, some vaccine-preventable infections includ-
ing influenza, pneumococcal diseases including pneumo-
nia and invasive pneumococcal disease (IPD) such as bac-
teremia or meningitis, HZ and human papillomavirus in-
fection all occur more frequently in patients with rheu-
matic disease [1,2,19]. 
1) Seasonal influenza
The risk of admission for influenza is higher in elderly 
patients of ≥65 year-old with rheumatic disease, com-
pared with elder individuals with no underlying medical 
condition [20,21]. The increased risk of influenza and its 
complications such as pneumonia in patients with RA 
was revealed by a large retrospective cohort study which 
were conducted with the matched healthy individuals 
[22]. The incidence of influenza and its complications 
was higher in patients with RA than in the healthy con-
trols (409.33 vs. 306.12 cases/100,000 patient-years and 
2.75-fold higher, respectively) [22]. 
2) Herpes zoster
Several studies showed patients with rheumatic disease 
were vulnerable to develop HZ. HZ could result in 
long-term morbidities including recurrence of skin lesion 
or postherpetic neuralgia (PHN) [2,23-28]. RA was an in-
dependent risk factor for occurrence of HZ (hazard ratio 
1.65 to 1.91, compared with healthy individuals) with a 
wide range in incidence (0.55∼12.1 cases/1,000 pa-
tient-years) in patients with rheumatic disease [23]. A 
systematic review indicated an increased risk of HZ in pa-
tients with RA treated with TNF-α antagonists, com-
pared with patients treated with nonbiologic DMARDs 
[29,30]. The immunosuppressive drugs, combined use of 
rituximab and steroids, could affect risk of HZ develop-
ment [31-33].
3) Streptococcus pneumoniae
Retrospective cohort studies have shown that patients 
with rheumatic disease were more likely than the healthy 
individuals to be admitted for pneumococcal disease 
[34]. Relative risk were 5.0 for systemic lupus eryth-
ematosus, 4.2 for scleroderma, 3.2 for Sjögren syndrome 
and 2.47 for RA [35-37].
Characteristics of recommending vaccines in 
patients with rheumatic disease and effect of 
biologics on vaccine efficiency or 
immunogenicity
Previous vaccination history should be thoroughly as-
sessed in initial evaluation of patients with rheumatic dis-
ease, especially before starting treatment with biologic 
agent. In particular, timing of vaccination should be care-
fully considered in patients who are already taking bio-
logic therapy, because some agents such as rituximab and 
abatacept could significantly decrease the efficacy of 
vaccines. Therefore, vaccine should ideally be admini-
stered to patients with rheumatic disease during stable 
disease without severe immunocompromised status, 
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Table 1. The remarkable characteristics of the vaccines considering in patients with rheumatic disease [14] 
Vaccines General consideration Precautions
Seasonal 
  influenza
• Strongly recommended in all patients with 
rheumatic disease every year
• Encouragement of vaccination in people who are 
closely contact with patients (e.g., family 
members)
Inactivated • IM or ID injection
• Quadrivalent vaccine will be more proper 
than trivalent
• Can be administered during therapy with 
TNF-α antagonist, tocilizumab, and abatacept
• Formulation including adjuvant can be used 
• Rituximab can significantly reduce the efficacy
• Should be vaccinated at least 6 months after the 
start and 4 weeks before the next injection of 
rituximab
 Live-attenuated • Nasal application
• Should be avoid in highly 
immunocompromised status
Streptococcus 
  pneumoniae
• Strongly recommended in all patients with 
rheumatic disease
• Can be administered during therapy with 
TNF-α antagonist, tocilizumab, and abatacept
• Important to strictly comply the guideline for time
interval between PCV13 and PPSV23 as well as 
time of boosting of PPSV23
• PCV13 and PPSV23 should not be 
co-administrated
• Should be separated at least 8 weeks between 
two vaccination
 PCV-13 • With preventive effect for non-bacteremic 
pneumonia as well as IPD
• Induce humoral and cellular immunity
 PPSV-23 • Without preventive effect for non-bacteremic 
pneumonia
• Induce only humoral immunity
Herpes zoster • Need to be considered for maintenance of 
long-term effectiveness, especially at old age of 
＞80-year-old
• Can prevent PHN as well as recurrence of HZ
 Live-attenuated • Has been used in general population
• Should be avoid in highly 
immunocompromised status
 Subunit • Inactivated vaccine
• Not approved, not available
IM: intramuscular, ID: intradermal, TNF: tumor necrosis factor, PCV: pneumococcal conjugate vaccine, PPSV: pneumococcal 
polysaccharide vaccine, IPD: invasive pneumococcal disease, PHN: postherpetic neuralgia, HZ: herpes zoster.
even though all recommended vaccines generally can be 
administered during TNF-α antagonists and tocilizumab 
therapy.
Evaluating the efficacy of vaccination should use clinical 
endpoints which indicate the significant decline of in-
cidence or prevalence for the infectious disease with fol-
low-up during certain period. However, there were a little 
studies using clinical endpoints and almost of studies 
have investigated the efficiency of vaccines by im-
munogenicity measuring humoral (antibody [Ab] titer) 
or cell-mediated immune responses in patients with 
rheumatic disease [38-40]. In spite of lacking of definite 
evidence for disease prevention, the vaccination for quad-
rivalent inactivated seasonal influenza, S. pneumoniae and 
tetanus-diphtheria-pertussis are generally and strongly 
recommended in all patients with rheumatic disease. 
Table 1 is summarized some remarkable characteristics of 
recommend vaccines in patients with rheumatic disease.
1) Seasonal influenza
The annual vaccination of inactivated seasonal influenza 
should be strongly recommended in all patients with 
rheumatic disease [14,41]. Currently, there is two types 
of trivalent and quadrivalent in killed inactivated influen-
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za vaccine. The quadrivalent vaccine is composed of four 
strains for each two influenza A (H1N1 and H3N2) and B 
(Yamagata and Victoria lineage). The trivalent vaccine is 
same with quadrivalent except one strain of type B. 
The attack rate of lower respiratory tract infection by in-
fluenza virus was significantly lower in influenza-vacci-
nated patients with RA compared than those without vac-
cination (relative risk 0.83, p＜0.01) [39,42]. The hae-
magglutinin inhibition (HI) titers for each influenza anti-
gen of ≥1:40 is considered seroprotective in patients 
with rheumatic disease like as in the general population, 
even though seroprotection levels may be not identical 
with clinical efficiency of influenza protection. On the ba-
sis of achievement of seroprotection, the efficacy of influ-
enza vaccination of patients with RA and healthy in-
dividuals has been shown to be similar. In spite of some 
previous conflicting reports, most studies revealed nei-
ther TNF-α antagonists (adalimumab, certolizumab, 
etanercept, and infliximab) nor tocilizumab (monoclonal 
antibody [mAb] against interleukin-6 receptor) ham-
pered humoral immune responses to influenza vacci-
nation [15,42-52]. 
The time interval between biologics administration and 
vaccination need to be considered. When patients with 
RA were vaccinated 3 weeks after administration of in-
fliximab, a trend towards a lower humoral immune re-
sponse measured by HI titers was observed as compared 
with those vaccinated on the day of infliximab admin-
istration [49]. 
In contrast to DMARDs and TNF-α antagonists, many 
studies reported that rituximab of mAb against CD20 se-
verely and abatacept of cytotoxic T-lymphocyte-asso-
ciated protein (CTLA)-4 inhibitor significantly decreased 
HI titers and seroconversion/seroprotection rates after 
influenza vaccination [53-58]. Patients who were vacci-
nated influenza 6∼10 months after rituximab had a bet-
ter seroprotective response that those vaccinated 4∼8 
weeks after rituximab [53-55]. Therefore, it will be more 
appropriate to vaccinate the patients before starting rit-
uximab, or, if not possible, at least 6 months after the start 
and 4 weeks before the next therapy [18].
The CD8+ cytotoxic T cell immune responses of pa-
tients with rheumatic disease to influenza vaccination 
may be decreased, which might be associated with in-
appropriate clearance of influenza in spite of enough se-
roprotection level [59,60]. However, the boosting of addi-
tional dose at 3∼4 weeks after initial vaccination is not 
recommended.
2) Streptococcus pneumoniae 
The vaccination for S. pneumoniae is strongly recom-
mended in immunocompromised patients with rheu-
matic disease treating biologic agents irrespective of age 
[14,41,61]. The pneumococcal vaccine are divided into 
two different formulations, polysaccharide or protein 
conjugate. The 23-valent pneumococcal polysaccharide 
vaccine (PPSV23) has been widely used in adults to pro-
vide protection against 23 among ≥90 serotypes of S. 
pneumoniae, which can prevent IPD including sepsis 
and/or meningitis with or without pneumonia rather 
than non-bacteremic pneumococcal pneumonia alone 
[62,63]. The 13-valent pneumococcal conjugate vaccine 
(PCV13) typically induce more robust humoral and cel-
lular immune responses than do polysaccharide vaccines 
that elicit Ab-producing humoral immunity alone 
[63,64]. The long-term large cohort study showed that 
PCV13 has a good protective effect for community-ac-
quired pneumococcal pneumonia as well as IPD [65]. 
For this reason, PCV13 has been recommended in pneu-
mococcal vaccine-naïve immunocompromised patients 
with rheumatic disease aged ≤64-year-old, followed by 
PPSV23 vaccination at least 8 weeks later or ideally 6∼12 
months later, with subsequent doses of PPSV23 at inter-
vals of 5 years because of the decline of protective Abs 
over time [66]. The patients who previously received 
PPSV23 at age ≥65-year-old, vaccination of PCV13 is 
recommended at least 1 year later of PPSV23 admin-
istration [66]. The falling rate of Abs in patients with 
rheumatic disease would be more rapid than those with-
out rheumatic disease [67]. However, there are no any 
consensus or clinical studies to support effectiveness of 
short-term boosting of PPSV23 in patients with rheu-
matic disease. Physicians should be careful of adequate 
time interval and sequence between PCV13 and PPSV23 
vaccination as well as boosting time of PPSV23 according 
to previous vaccine history of PPSV23 [64,66]. Most im-
portant caution is that PPSV23 and PCV13 should not be 
simultaneously administrated, because of increased local 
reactogenicity [64,66].
Most of studies about effectiveness of PPSV23 or PCV13 
in patients with rheumatic disease regardless of TNF-α 
antagonists or tocilizumab therapy showed no difference 
compared with controls [68-70]. Although PCV13 could 
reduce overall disease burden of S. pneumoniae than 
PPSV23, because PCV13 has potential effectiveness 
against non-bacteraemic pneumococcal pneumonia as 
well as IPD, there are no data regarding this issue in rheu-
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matic disease patients treated with biologic [64,65].
3) Herpes zoster
The immunocompromised status in patients with rheu-
matic disease could cause the frequent recurrence of HZ 
and/or severe disseminated skin lesion along with more 
violent pain. This may be associated with agonizing 
and/or prolonged PHN especially at old age [71,72]. This 
clinical impacts generate continuous controversy and 
conduct clinical studies about the safety and effectiveness 
of HZ vaccine in rheumatic disease patients receiving cer-
tain biologic agent. 
As the currently available HZ vaccine (Zostavax; Merck, 
Whitehouse Station, NJ, USA) contains live attenuated 
virus, its use should be avoided in patients with rheu-
matic disease in general, even though the balance be-
tween safety issue and protective effect are debating 
[1,18,73]. The Zostavax has relatively low effect for re-
duction of HZ risk compared than subunit vaccine and 
continuously decline of vaccine efficacy over time [74-76]. 
It is possible that the Zostavax was essentially no pro-
tective effect by about 10 year after vaccination, when the 
risk for occurrence of HZ and/or postherpetic neuralgia 
would be highest [74]. The newly developed, but not 
available adjuvanted recombinant Varicella-zoster virus 
subunit vaccine, that is not live vaccine, showed the bet-
ter vaccine efficiency in all age group of ≥50 year-old 
[76,77]. However, the further study need to evaluate the 
sustained effectiveness over time especially at over 
80-year-old. The advantage as inactivated vaccine raises 
the hope that subunit HZ vaccine can be used in severely 
immunocompromised rheumatic disease patients with 
guaranteed safety. The study will be warranted to eval-
uate the efficacy of subunit vaccine in rheumatic disease 
patients receiving several different biologics.
Vaccines which should be avoided or carefully 
administered in rheumatic disease patients 
receiving immunosuppressive biologic agents
All live attenuated vaccines are contraindicated for rheu-
matic disease patients receiving highly immunosuppressive 
biologic agents, because these vaccinations may be asso-
ciated with poor safety profiles mainly caused by uncon-
trolled replication of bacteria or virus of essential in-
gredients for vaccine [13,78-80]. Vaccination itself could 
induce the critical disseminated infectious disease 
[13,78,80]. These include the followings; (1) nasal spray 
live attenuated trivalent influenza vaccine, (2) live atte-
nuated HZ vaccine (Zostavax), (3) BCG (Bacillus Cal-
mette–Guérin), (4) yellow fever, (5) measles, mumps and 
rubella (MMR), (6) rotavirus, (7) Ty21a oral typhoid.
If the live attenuated vaccine is inevitably necessary in 
special case, physicians must use these with great caution. 
Initiation of TNF-α antagonist therapy should be de-
layed at least 2∼4 weeks after administration of live atte-
nuated vaccine, especially HZ vaccine [81]. It is safe to 
wait a more than of 4 weeks between any live attenuated 
vaccination and highly immunosuppressive biologic 
agent therapy.
CONCLUSION
The patients with rheumatic disease can have vulner-
ability to several infectious diseases compared to the gen-
eral population. Therefore, a couple of vaccination should 
be strongly considered with carefulness. In general, the 
quadrivalent seasonal influenza and pneumococcal vacci-
nation (both PCV13 and PPSV23) need to be admini-
stered to all patients with rheumatic disease irrespective 
of their medication status, even if the vaccination before 
use of highly immunosuppressive drugs including bio-
logic will be guaranteed to be more adequate immune 
response. The negative effect of rituximab on vaccine effi-
cacy has been well known. Therefore, it should be taken 
into account of appropriate time interval between vacci-
nation and rituximab injection. All live attenuated vac-
cines including currently available HZ vaccine (Zostervax) 
are generally contraindicated in severely immunosup-
pressive patients with rheumatic disease.
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